Metabolomics Explained for Non-Scientists

Biology uses the suffix "omics" for fields that measure a whole class of molecules at once. A simple way to see how they relate is to follow the flow of biological information.

EMBL-EBI explains why the last row matters: metabolites and their concentrations, unlike other omics measures, directly reflect the underlying biochemical activity and state of cells and tissues, so metabolomics "best represents the molecular phenotype." Phenotype means the observable state of an organism, as opposed to its genetic code.

The Wikipedia overview of the field puts it in similar terms: while gene and protein data show what a cell is set up to produce, metabolic profiling can give an instantaneous snapshot of the physiology of that cell.

An analogy helps. Your genome is the cookbook. Your metabolome is what is actually cooking in the kitchen today, which depends on the cookbook but also on what was in the fridge, who was cooking and how busy the kitchen was.

Metabolites are hard to measure together because they are chemically so different. The precision medicine review notes that metabolomics aims to measure molecules with disparate physical properties, ranging from very water-soluble organic acids to very nonpolar lipids. Laboratories therefore often split the metabolome into groups and use a different method for each.

Two main technologies do the measuring:

• Mass spectrometry (MS) weighs molecules very precisely and is usually paired with a separation step, such as liquid chromatography (LC-MS) or gas chromatography (GC-MS), so that molecules reach the detector one group at a time.
• Nuclear magnetic resonance (NMR) spectroscopy uses magnetic fields to identify molecules by their structure. A review in Clinical Cancer Research notes that metabolites are detected by either nuclear magnetic resonance spectroscopy or mass spectrometry in cells, tissues and biofluids.

An overview of clinical metabolomics in the journal Metabolism Open notes that liquid chromatography-mass spectrometry is the predominant analytical method used in metabolomics, particularly untargeted, and that clinical metabolomics studies body fluids such as plasma, urine, saliva and cerebrospinal fluid, as well as tissues.

The sample matters. The same overview describes blood plasma as containing a multitude of metabolites that reflect organ metabolic activity. Different sample types capture different parts of metabolism, so results from one sample type cannot simply be compared with results from another.

This is the distinction that most often confuses non-specialists, and it shapes what a result can and cannot tell you.

Metabolon, a metabolomics company, describes the difference this way: untargeted metabolomics is a global and comprehensive analysis of all metabolites in a sample, including unknown targets, while targeted metabolomics measures a defined set of characterized and biochemically annotated analytes.

Metabolon also describes a middle ground. "Semi-targeted" approaches measure a larger defined list of hundreds of metabolites, often without a single hypothesis, and researchers increasingly combine methods: untargeted screening to find candidate markers, followed by targeted analysis to verify them.

A detailed methods paper on targeted metabolomics explains where the precision comes from: it measures defined groups of chemically characterized metabolites and, through the use of internal standards, can quantify them in a quantitative or semi-quantitative way.

For a non-scientist reading a report, the practical question is simple. Is this a defined panel of known molecules, or an exploratory scan? The answer tells you how much weight each individual number can bear.

Medicine has used single metabolites for a long time. The precision medicine review gives two classic examples: blood glucose test strips for diabetes and measuring phenylalanine in newborns to screen for phenylketonuria, an inherited metabolic disorder. Metabolomics extends that idea from one molecule to many.

Current research uses fall into a few groups.

• Cardiometabolic disease. The Metabolism Open overview notes that metabolomics studies have been valuable in understanding cardiometabolic disorders, and that branched-chain amino acids are particularly prominent among metabolites associated with type 2 diabetes in large studies.
• Cancer. Cancer changes how cells use energy. A review of metabolomics in cancer describes how it has deepened understanding of how cancer cells use glycolysis, known as the Warburg effect, to produce the building blocks tumors need to grow. A review in Clinical Cancer Research describes potential uses in early detection and diagnosis of cancer and as predictive and pharmacodynamic markers of drug effect.
• Biomarkers and drug targets. A review in Molecules describes metabolites as links between genotype and phenotype that are attractive biomarkers for diagnosis, prognosis and treatment, and as a route to finding new therapeutic targets.
• Precision medicine. Because metabolites reflect both genes and environment, they can help characterize an individual's metabolic state, which is one goal of personalized care.

Whether you are a patient, an investor reading about a diagnostics company or a manager evaluating a wellness benefit, a few principles help.

1. Know what kind of number it is. An absolute concentration and a relative signal are different things. A relative value says how one sample compares with others measured the same way, not how much of a molecule is present in standard units.
2. Know the comparison group. Many results are expressed against a reference population. Who was in that population, and how similar they are to the person tested, affects interpretation.
3. Look at patterns, not single values. Metabolites work in pathways. A coherent pattern across related molecules is more informative than one value slightly out of range.
4. Remember what influences the result. The Metabolism Open overview notes that metabolic signatures are influenced by genetics, epigenetics, dietary patterns and environment. A recent meal, medications, supplements, exercise and the time of collection can all matter.
5. Track change over time. A single snapshot is useful. Repeated measurements on the same platform, under similar conditions, show direction.
6. Confirm with established tests. A metabolomics finding is a signal to investigate. Diagnosis relies on a clinician and on validated tests for the specific condition.

Metabolomics is powerful but young as a clinical tool, and the sources are candid about the gaps.

• The metabolome is not fully mapped. The precision medicine review notes that researchers are still learning what actually constitutes the human metabolome.
• Discovery to clinic is slow. The same review observes that a decade or more has often passed between discovering a disease marker, validating it in human trials and implementing it as a routine clinical test.
• Unknowns are hard to identify. In untargeted work, Metabolon notes that the absence of reference standards makes identifying unknown metabolites challenging, and that detection is biased toward higher-abundance molecules.
• Findings must generalize. The Metabolism Open overview calls for more research to identify which metabolites consistently enhance clinical risk prediction across various populations and are causally linked to disease progression.
• Awareness is limited. The Clinical Cancer Research review notes a lack of knowledge in the oncology community about metabolomics and confusion about its methods and applications.

None of this makes metabolomics less useful. It means results should be read with an understanding of what was measured, how, and against whom.